News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
REICIN ALISE
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/15/2023 |
4
| REICIN ALISE (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 23,000 options to buy
@ $1.03, valued at
$23.7k
|
|
| 06/09/2023 |
4
| REICIN ALISE (Director) has filed a Form 4 on Sana Biotechnology, Inc.|
Txns:
| Granted 65,000 options to buy
@ $6.7, valued at
$435.5k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2020 |
4
| REICIN ALISE (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 18,000 options to buy
@ $16.32, valued at
$293.8k
|
|
| 11/22/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/04/2019 |
4
| REICIN ALISE (PRES., GLOBAL CLINICAL DEV.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 4,722 shares
@ $108.53, valued at
$512.5k
Exercised 11,903 restricted stock units
@ $0 |
|
| 07/15/2019 |
4
| REICIN ALISE (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 31,160 options to buy
@ $19.25, valued at
$599.8k
|
|
| 03/05/2019 |
4
| REICIN ALISE (PRES., GLOBAL CLINICAL DEV.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 37,660 restricted stock units
@ $0 |
|
| 11/02/2018 |
4
| REICIN ALISE (PRES., GLOBAL CLINICAL DEV.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 42,500 options to buy
@ $75.61, valued at
$3.2M
Granted 35,710 restricted stock units
@ $0 |
|
|
|